Phaseline

Companies › MOMA Therapeutics

MOMA Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MOMA-313
PARP inhibitor
–Phase 1Advanced Solid TumorMay 2027
MOMA-341–Phase 1Advanced Solid TumorNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06545942MOMA-313Phase 1Advanced Solid TumorOncologyMay 2027
NCT06974110MOMA-341Phase 1Advanced Solid TumorOncologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.